Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
11.12.2019 04:00:00 EET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12th.
The poster presentation, titled “A comprehensive tumor immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumors and the TME from a single FFPE sample,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT™. The poster will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response; utilizing analytics including: human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, immune cell deconvolution, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.
ImmunoID NeXT™ is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.
The presentation will be delivered by Robert Power, M.S., Product Manager, for Personalis.
Personalis will also be exhibiting during the conference (Exhibit #9). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210006093/en/
Contact information
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 13:45:00 EET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance review completion reached 99% and the employee survey response rate reached 89%. NIQ also introduced three new leadership development tracks, while Employee Assistance Program
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 13:42:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The manuscript, titled “Preoperative botensilimab with or without balstilimab for patients with resectable, locally advanced pMMR or dMMR colon cancer: the UNICORN trial by GONO,” was published in Nature Medicine and is available at DOI 10.1038/s41591-026-04710-1. The UNICORN trial enrolled 56 patients in four non-randomized cohorts of 14, evaluating BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. The study ass
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers2.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing the burden of prolonged depressive episodes without meaningful relief. The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while the condition takes a toll on their hope, identity, relationships and ability to fully engage in life.1 They also underscore the impact on caregivers and families, including substantial personal, emotional and financial sacrifices. “These results give voice to the realities faced
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale2.11.2026 12:00:00 EET | Press release
Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/ Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater control over its shape, size, thickness and structure. Reyva sample photography by Laurent Stevens Reyva grows collagen directly from animal cells and cultivates it through a proprietary process to create uniform sheets. The resulting material is then tanned to become real leather, made from the same natural material that gives conventional leather its strength, breathability and durability. It does so without t
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 10:52:00 EET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom